EA202091540A1 - Антитела к lilrb2 - Google Patents
Антитела к lilrb2Info
- Publication number
- EA202091540A1 EA202091540A1 EA202091540A EA202091540A EA202091540A1 EA 202091540 A1 EA202091540 A1 EA 202091540A1 EA 202091540 A EA202091540 A EA 202091540A EA 202091540 A EA202091540 A EA 202091540A EA 202091540 A1 EA202091540 A1 EA 202091540A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lilrb2
- antibodies
- cancer
- methods
- various embodiments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610050P | 2017-12-22 | 2017-12-22 | |
PCT/US2018/066819 WO2019126514A2 (en) | 2017-12-22 | 2018-12-20 | Antibodies for lilrb2 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091540A1 true EA202091540A1 (ru) | 2021-03-22 |
Family
ID=65041919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091540A EA202091540A1 (ru) | 2017-12-22 | 2018-12-20 | Антитела к lilrb2 |
Country Status (16)
Country | Link |
---|---|
US (4) | US10723798B2 (pt) |
EP (2) | EP3728318A2 (pt) |
JP (2) | JP7391868B2 (pt) |
KR (1) | KR20200103706A (pt) |
CN (1) | CN111699196A (pt) |
AR (1) | AR114002A1 (pt) |
AU (1) | AU2018389111A1 (pt) |
BR (1) | BR112020012650A2 (pt) |
CA (1) | CA3087166A1 (pt) |
CL (1) | CL2020001637A1 (pt) |
EA (1) | EA202091540A1 (pt) |
IL (1) | IL275268A (pt) |
MX (1) | MX2020006668A (pt) |
SG (1) | SG11202004806SA (pt) |
TW (1) | TWI833724B (pt) |
WO (1) | WO2019126514A2 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗-ilt4抗體及抗原結合片段 |
EA202091540A1 (ru) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
EP3762426A2 (en) * | 2018-03-06 | 2021-01-13 | Imcare Biotech, LLC | Serine protease inhibitor kazal (spik) compositions and methods |
CA3104530A1 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
MX2022003365A (es) * | 2019-09-20 | 2022-08-22 | Invectys SAS | Anticuerpos de un solo dominio dirigidos contra lilrb2. |
CA3164510A1 (en) * | 2020-01-13 | 2021-07-22 | Yasmin RAMSAY | Methods for the treatment of cancer |
US20230137672A1 (en) * | 2020-03-27 | 2023-05-04 | The Trustees Of Indiana University | Immunotherapeutic targets in multiple myeloma and methods for their identification |
AU2021265801A1 (en) * | 2020-05-01 | 2022-11-17 | Ngm Biopharmaceuticals, Inc. | ILt-binding agents and methods of use thereof |
EP3981789A1 (en) * | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
JP2024512395A (ja) * | 2021-03-09 | 2024-03-19 | ジャウンス セラピューティックス, インク. | がんの治療のための方法 |
WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
CN115975029A (zh) * | 2022-06-28 | 2023-04-18 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
CN114805580B (zh) * | 2022-06-28 | 2022-09-06 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
TW202409088A (zh) * | 2022-07-08 | 2024-03-01 | 中國商科望(蘇州)生物醫藥科技有限公司 | 抗lilrb2抗體及其用途 |
WO2024041315A1 (en) * | 2022-08-22 | 2024-02-29 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-lilrb2 antibodies and uses thereof |
WO2024073522A2 (en) * | 2022-09-28 | 2024-04-04 | Sparx Bioscience Limited | Antibodies binding to leukocyte immunoglobulin-like receptor subfamily b member 2 (lilrb2) and uses thereof |
WO2024150017A1 (en) | 2023-01-13 | 2024-07-18 | Akrivia Biomedics Limited | Method of profiling diseases |
WO2024160261A1 (en) * | 2023-02-02 | 2024-08-08 | Laekna Therapeutics Shanghai Co., Ltd. | Anti-lilrb1 and/or anti-lilrb2 antibodies and uses thereof |
CN117417454B (zh) * | 2023-12-19 | 2024-03-05 | 北京索莱宝科技有限公司 | 抗鸡IgY抗体及其应用 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP3690043A1 (en) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antibody composition-producing cell |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
US20040241167A1 (en) | 2001-06-25 | 2004-12-02 | Nicole Suciu-Foca | Ilt3 and ilt4-related compositons and methods |
AU2002345878A1 (en) | 2001-06-25 | 2003-01-08 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
JP2005532256A (ja) | 2001-11-14 | 2005-10-27 | イミユネツクス・コーポレイシヨン | 慢性関節リウマチを治療するためのlir機能の調節 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
PT1678314E (pt) | 2003-10-22 | 2012-11-27 | Keck Graduate Inst | Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide |
EA202091901A1 (ru) | 2003-11-05 | 2020-11-24 | Роше Гликарт Аг | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2295588B1 (en) * | 2004-05-27 | 2018-03-07 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses thefor |
JP2008528033A (ja) | 2005-01-27 | 2008-07-31 | ファイブ プライム セラピューティクス, インコーポレイテッド | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
JP2010509612A (ja) | 2006-11-14 | 2010-03-25 | ジェネンテック インコーポレイテッド | ニューロン再生の活性調節因子 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2008090959A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | エフェクター活性が増強された遺伝子組換え抗体組成物 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
CA2708492A1 (en) | 2007-12-11 | 2009-06-18 | Genetech, Inc. | Modulators of neuronal regeneration |
CN102089327A (zh) | 2008-05-13 | 2011-06-08 | 健泰科生物技术公司 | 抗PirB抗体 |
TW201247700A (en) | 2011-05-05 | 2012-12-01 | Baylor Res Inst | Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists |
WO2013181438A2 (en) | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
US10138286B2 (en) | 2013-03-12 | 2018-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
CN105324362B (zh) | 2013-03-15 | 2017-05-24 | 百时美施贵宝公司 | Ido抑制剂 |
AU2015264120A1 (en) * | 2014-05-22 | 2016-11-24 | Board Of Regents Of The University Of Texas System | LILRB2 and notch-mediated expansion of hematopoietic precursor cells |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
AU2016218900A1 (en) | 2015-02-11 | 2017-08-24 | University Health Network | Methods and compositions for modulating LILR proteins |
JP6730996B2 (ja) * | 2015-03-06 | 2020-07-29 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 抗lilrb抗体ならびにがんの検出及び処置におけるその使用 |
RU2742241C2 (ru) | 2015-03-23 | 2021-02-04 | Джоунс Терапьютикс, Инк. | Антитела к icos |
EP3326641B1 (en) * | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
TWI781120B (zh) | 2016-11-02 | 2022-10-21 | 美商永斯醫療股份有限公司 | Pd-1之抗體及其用途 |
TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗-ilt4抗體及抗原結合片段 |
EA202091540A1 (ru) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
CA3104530A1 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
-
2018
- 2018-12-20 EA EA202091540A patent/EA202091540A1/ru unknown
- 2018-12-20 CN CN201880083004.7A patent/CN111699196A/zh active Pending
- 2018-12-20 BR BR112020012650-0A patent/BR112020012650A2/pt unknown
- 2018-12-20 JP JP2020554055A patent/JP7391868B2/ja active Active
- 2018-12-20 CA CA3087166A patent/CA3087166A1/en active Pending
- 2018-12-20 TW TW107146218A patent/TWI833724B/zh active
- 2018-12-20 MX MX2020006668A patent/MX2020006668A/es unknown
- 2018-12-20 EP EP18836765.0A patent/EP3728318A2/en active Pending
- 2018-12-20 WO PCT/US2018/066819 patent/WO2019126514A2/en unknown
- 2018-12-20 KR KR1020207019622A patent/KR20200103706A/ko unknown
- 2018-12-20 SG SG11202004806SA patent/SG11202004806SA/en unknown
- 2018-12-20 AU AU2018389111A patent/AU2018389111A1/en active Pending
- 2018-12-20 AR ARP180103767A patent/AR114002A1/es unknown
- 2018-12-20 US US16/228,084 patent/US10723798B2/en active Active
- 2018-12-20 EP EP22216659.7A patent/EP4219559A3/en active Pending
-
2020
- 2020-03-11 US US16/815,837 patent/US20200207856A1/en not_active Abandoned
- 2020-06-10 IL IL275268A patent/IL275268A/en unknown
- 2020-06-17 CL CL2020001637A patent/CL2020001637A1/es unknown
- 2020-07-14 US US16/928,663 patent/US11359019B2/en active Active
-
2022
- 2022-06-13 US US17/838,426 patent/US20230053631A1/en active Pending
-
2023
- 2023-11-22 JP JP2023197857A patent/JP2024026140A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190194327A1 (en) | 2019-06-27 |
MX2020006668A (es) | 2020-10-07 |
US20200207856A1 (en) | 2020-07-02 |
SG11202004806SA (en) | 2020-06-29 |
IL275268A (en) | 2020-07-30 |
KR20200103706A (ko) | 2020-09-02 |
AU2018389111A1 (en) | 2020-06-18 |
BR112020012650A2 (pt) | 2020-12-01 |
EP3728318A2 (en) | 2020-10-28 |
US10723798B2 (en) | 2020-07-28 |
WO2019126514A2 (en) | 2019-06-27 |
JP2024026140A (ja) | 2024-02-28 |
US11359019B2 (en) | 2022-06-14 |
US20230053631A1 (en) | 2023-02-23 |
CL2020001637A1 (es) | 2021-02-19 |
TW201930357A (zh) | 2019-08-01 |
CN111699196A (zh) | 2020-09-22 |
WO2019126514A3 (en) | 2019-08-08 |
EP4219559A3 (en) | 2023-10-18 |
EP4219559A2 (en) | 2023-08-02 |
AR114002A1 (es) | 2020-07-08 |
TWI833724B (zh) | 2024-03-01 |
CA3087166A1 (en) | 2019-06-27 |
JP2021506344A (ja) | 2021-02-22 |
JP7391868B2 (ja) | 2023-12-05 |
US20200339690A1 (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091540A1 (ru) | Антитела к lilrb2 | |
EA202090104A1 (ru) | Молекулы антител к cd73 и пути их применения | |
CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
CY1124730T1 (el) | Αντισωματα εναντι pd-1 και χρησεις αυτων | |
CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
EA201691488A1 (ru) | Молекулы антител против pd-1 и их применения | |
MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
BR112017020054A2 (pt) | anticorpos para icos | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
EA201790413A1 (ru) | Антитела против tigit | |
EA201690443A1 (ru) | Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения | |
EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
EA201990978A1 (ru) | Антитела против pd-1 | |
EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода |